Baine MJ, Verma V, Schonewolf CA, Lin C, Simone CB 2nd (2018) Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer. Lung Cancer 118:20–26
Article
Google Scholar
Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M et al (2020) Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. J Clin Invest 130(2):612–624
Article
Google Scholar
Chang H, Lee SJ, Lim J, Lee JS, Kim YJ, Lee WW (2019) Prognostic significance of metabolic parameters measured by (18)F-FDG PET/CT in limited-stage small-cell lung carcinoma. J Cancer Res Clin Oncol 145(5):1361–1367
Article
CAS
Google Scholar
Chardin D, Paquet M, Schiappa R, Darcourt J, Bailleux C, Poudenx M et al (2020) Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer 8(2):e000645
Article
Google Scholar
Dall’Olio FG, Calabro D, Conci N, Argalia G, Marchese PV, Fabbri F et al (2021) Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. Eur J Cancer 150:99–107
Article
CAS
Google Scholar
Detterbeck FC (2018) The eighth edition TNM stage classification for lung cancer: what does it mean on main street? J Thorac Cardiovasc Surg 155(1):356–359
Article
Google Scholar
Dolan RD, Maclay JD, Abbass T, Colville D, Buali F, MacLeod N et al (2020) The relationship between (18)F-FDG-PETCT-derived tumour metabolic activity, nutritional risk, body composition, systemic inflammation and survival in patients with lung cancer. Sci Rep 10(1):20819
Article
CAS
Google Scholar
Eude F, Guisier F, Salaun M, Thiberville L, Pressat-Laffouilhere T, Vera P et al (2022) Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab. Ann Nucl Med 36(3):224–234
Article
CAS
Google Scholar
Freudenberg LS, Paez D, Giammarile F, Cerci J, Modiselle M, Pascual TNB et al (2020) Global impact of COVID-19 on nuclear medicine departments: an international survey in april 2020. J Nucl Med 61(9):1278–1283
Article
CAS
Google Scholar
Hashimoto K, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y et al (2020) Potential of FDG-PET as prognostic significance after anti-PD-1 antibody against patients with previously treated non-small cell lung cancer. J Clin Med 9(3):725
Article
CAS
Google Scholar
Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z et al (2014) Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med 55(10):1584–1590
Article
CAS
Google Scholar
Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC et al (2014) Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 41(1):50–58
Article
CAS
Google Scholar
Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ et al (2015) Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging 42(2):241–251
Article
CAS
Google Scholar
Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V et al (2019) (18)F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 46(9):1859–1868
Article
CAS
Google Scholar
Lambin P, Zindler J, Vanneste B, van de Voorde L, Jacobs M, Eekers D et al (2015) Modern clinical research: how rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta Oncol 54(9):1289–1300
Article
Google Scholar
Lee PBJ, Lavori PW, Weerasuriya DK, Quon A, Le QT et al (2012) Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non–small-cell lung cancer. Clin Lung Cancer 13(1):52–58
Article
Google Scholar
Li X, Wang D, Yu L (2019) Prognostic and predictive values of metabolic parameters of (18)F-FDG PET/CT in patients with non-small cell lung cancer treated with chemotherapy. Mol Imaging 18:108735
Article
Google Scholar
Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R et al (2012) Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 39(1):27–38
Article
CAS
Google Scholar
Liu J, Dong M, Sun X, Li W, Xing L, Yu J (2016) Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS ONE 11(1):e0146195
Article
Google Scholar
Monaco L, Gemelli M, Gotuzzo I, Bauckneht M, Crivellaro C, Genova C et al (2021) Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (NSCLC): a real world experience. Cancers (basel) 13(7):1634
Article
CAS
Google Scholar
Oliveira FR, de Oliveira SA, de Lima MD, Toro IF, de Souza TF, Amorim BJ, Barbeiro AS, Etchebehere E (2022) The ratio between the whole-body and primary tumor burden, measured on 18F-FDG PET/CT studies, as a prognostic indicator in advanced non-small cell lung cancer. Radiol Bras Set 54(5):289–294
Article
Google Scholar
Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V et al (2019) Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. Ann Nucl Med 33(12):937–944
Article
CAS
Google Scholar
Peng SM, Ren JJ, Yu N, Xu JY, Chen GC, Li X et al (2022) The prognostic value of the Naples prognostic score for patients with non-small-cell lung cancer. Sci Rep 12(1):5782
Article
CAS
Google Scholar
Popinat G, Cousse S, Goldfarb L, Becker S, Gardin I, Salaun M et al (2019) Sub-cutaneous fat mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. Oncoimmunology 8(5):e1580128
Article
Google Scholar
Pu Y, Zhang JX, Liu H, Appelbaum D, Meng J, Penney BC (2018) Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nucl Med Mol Imaging 45(12):2079–2092
Article
Google Scholar
Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 377(9):849–861
Article
CAS
Google Scholar
Rocha ALG, da Conceicao MAM, da Cunha Sequeira Mano FXP, Martins HC, Costa G, Dos Santos Oliveiros Paiva BCB et al (2021) Metabolic active tumour volume quantified on [(18)F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients. J Cancer Res Clin Oncol 147(12):3601–3611
Article
Google Scholar
Santos DF, Takahashi ME, Camacho M, de Lima MdCL, Amorim BJ, Rohren EM et al (2022) Whole-body tumor burden in PET/CT expert review. Clin Transl Imaging. https://doi.org/10.1007/s40336-022-00517-5
Article
Google Scholar
Seban RD, Assie JB, Giroux-Leprieur E, Massiani MA, Soussan M, Bonardel G et al (2020) Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab. Cancers (basel) 12(8):2234
Article
CAS
Google Scholar
Shea M, Costa DB, Rangachari D (2016) Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 10(2):113–129
Article
CAS
Google Scholar
Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48(6):932–945
Article
Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Article
Google Scholar
Vanhove K, Mesotten L, Heylen M, Derwael R, Louis E, Adriaensens P et al (2018) Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. Cancer Treat Res Commun 15:7–12
Article
Google Scholar
Ventura L, Scarlattei M, Gnetti L, Silini EM, Rossi M, Tiseo M et al (2020) Prognostic value of [(18)F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience. Tumori J 106:212–222
Article
CAS
Google Scholar
Wang XY, Zhao YF, Liu Y, Yang YK, Zhu Z, Wu N (2017) Comparison of different automated lesion delineation methods for metabolic tumor volume of 18F-FDG PET/CT in patients with stage I lung adenocarcinoma. Medicine (Baltimore) 96(51):e9365
Article
Google Scholar
Woodard GA, Jones KD, Jablons DM (2016) Lung cancer staging and prognosis. Cancer Treat Res 170:47–75
Article
Google Scholar
Xie D, Allen MS, Marks R, Jiang G, Sun Z, Nichols F et al (2018) Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers. Eur J Cardiothorac Surg 53(6):1214–1222
Article
Google Scholar
Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Shiono A, Miura Y et al (2020) Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 >/= 50. Sci Rep 10(1):14990
Article
Google Scholar
Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5(3):288–300
Article
CAS
Google Scholar